Initial core biopsy demonstrated “invasive poorly differentiated breast carcinoma with high-grade neuroendocrine features and necrosis.” Receptor status demonstrated estrogen receptor (ER) negativity, progesterone receptor (PR) positivity, and human epidermal growth factor receptor 2 (HER-2) negativity by immunohistochemistry. The gene discussed is ERBB2; the disease is breast carcinoma.